Modern Chinese Medicine Group Delays Circular on Major Acquisition

An update from Modern Chinese Medicine Group Co. Ltd. ( (HK:1643) ) is now available.

Modern Chinese Medicine Group Co. Ltd. has announced a delay in sending a shareholder circular related to a major transaction involving the acquisition of sale shares, which was originally expected to be dispatched by 9 February 2026. The postponement is attributed to the need for more time to finalise information, including the consolidated audited report of the target group for the three years ended 31 December 2025, and the company now expects to issue the circular by 30 April 2026, subject to a waiver from strict compliance with Listing Rule 14.41(a).

The company has applied to the Hong Kong Stock Exchange for this waiver, which has not yet been granted, and has indicated it will make further announcements as appropriate. The delay underscores procedural and regulatory constraints around major transactions for Hong Kong–listed firms, and signals that shareholders and other stakeholders may need to wait longer for full disclosure on the acquisition’s financial details and implications.

The most recent analyst rating on (HK:1643) stock is a Hold with a HK$0.91 price target. To see the full list of analyst forecasts on Modern Chinese Medicine Group Co. Ltd. stock, see the HK:1643 Stock Forecast page.

More about Modern Chinese Medicine Group Co. Ltd.

Modern Chinese Medicine Group Co., Ltd., incorporated in the Cayman Islands and listed in Hong Kong, operates in the pharmaceutical and traditional Chinese medicine sector. The company is governed by a board comprising three executive directors and three independent non-executive directors, reflecting a standard corporate governance structure for a Hong Kong–listed issuer.

Average Trading Volume: 989,900

Technical Sentiment Signal: Buy

Current Market Cap: HK$554.4M

For detailed information about 1643 stock, go to TipRanks’ Stock Analysis page.